Oculis Holding AG (OCS)

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,821
Open	8.55
Previous Close	8.02
Day's Range	7.50 - 8.55
52-Week Range	7.50 - 13.95
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About OCS

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: OCS